产品名称	MIA PaCa-2人胰腺癌细胞
货号	ZQ0454
产品介绍	MIA PaCa-2细胞系来源于一名65岁男性胰腺癌组织，是肿瘤研究领域不可或缺的资产。其被广泛用于胰腺导管腺癌(PDAC)的研究，这是一种众所周知的侵袭性和致死性癌症类型。该细胞系提供了反映PDAC细胞特征的实体瘤模型。该细胞系的关键属性之一是其遗传谱，其中包括KRAS和TP53等关键基因的突变，这些基因是胰腺癌患者观察到的遗传景观的象征。 该细胞被广泛用来研究胰腺癌的各个方面发展,转移和抵抗治疗，也是评估化疗药物疗效的重要工具。此外，该细胞系是探索癌细胞存活和转移的关键信号通路的重要资源，包括MAPK、PI3K/AKT和Wnt通路。利用MIA PaCa-2细胞的研究也揭示了癌细胞与其微环境之间的动态相互作用。MIA PaCa-2强大的体外生长能力及其在异种移植模型中形成肿瘤的能力使其特别适合于检查癌症进展和肿瘤发生机制。综上所述，Mia Paca-2细胞系在胰腺癌研究中的广泛应用，仍然是全世界科学家的重要资源。 据报道，该细胞系倍增时间约40小时，在软琼脂中的集落形成效率约19％。该细胞系对天冬酰胺酶敏感。 【注意事项】：该细胞贴壁较慢，传代或复苏48小时后方可贴壁完全。该细胞正常情况下为贴壁细胞与圆形漂浮细胞同时存在。换液时需注意保留漂浮细胞，传代时需将贴壁细胞和漂浮细胞一同收集后再传代。
种属	人
性别/年龄	男/65岁
组织	胰腺
疾病	胰腺导管腺癌
细胞类型	肿瘤细胞
形态学	带有漂浮圆形细胞的附着上皮
生长方式	贴壁
倍增时间	大约18~40小时
培养基和添加剂	DMEM（品牌：中乔新舟  货号：ZQ-100）+10%FBS（品牌：中乔新舟  货号：ZQ0500）+1%P/S（中乔新舟  货号：CSP006）+2.5%马血清（中乔新舟 货号：ZQH500）+1% Sodium Pyruvate 100 mM Solution（中乔新舟  货号：CSP003）
推荐完全培养基货号	ZM0454
生物安全等级	BSL-1
STR位点信息	D5S818: 12,13 D13S317: 12,13 D7S820: 12,13 D16S539: 10,13 vWA: 15 THO1: 9,10 Amelogenin: X TPOX: 9 CSF1PO: 10
培养条件	95%空气，5%二氧化碳；37℃
抗原表达/受体表达	***
基因表达	***
保藏机构	ATCC; CRL-1420 DSMZ; ACC-733 ECACC; 85062806 JCRB; JCRB0070
供应限制	仅供科研使用

货号	ZQ0454
发货规格	活细胞：T25培养瓶*1瓶或者1ml 冻存管*1支（细胞量约为5 x 10^5 cells/vial）二选一
发货形式	活细胞：常温运输；冻存管：干冰运输
储存温度	活细胞：培养箱；冻存管：液氮罐
产地	中国
供应限制	仅供科研使用

论文标题： NEAT1/miR-101-dependent Up-regulation of DNA-PKcs Enhances Malignant Behaviors of Pancreatic Ductal Adenocarcinoma Cells
DOI： 10.7150/jca.58824
发表时间： 2021-07-25
期刊： Journal of Cancer
影响因子： 4.207
货号： ZQ0454
产品名称： MIA PaCa-2 cells
原文链接： https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8364653/

论文标题： Anillin is a prognostic factor and is correlated with genovariation in pancreatic cancer based on databases analysis
DOI： 10.3892/ol.2020.12368
发表时间： 2020-12-10
期刊： Oncology Letters
影响因子： 2.311
货号： ZQ0454
产品名称： MIA PaCa-2 cells
原文链接： https://www.spandidos-publications.com/10.3892/ol.2020.12368

论文标题： HOXB5 promotes proliferation, migration, and invasion of pancreatic cancer cell through the activation of the GSK3β/β-catenin pathway
DOI： 10.1097/CAD.0000000000000948
发表时间： 2020-09-01
期刊： ANTI-CANCER DRUGS
影响因子： 2.26
货号： ZQ0454
产品名称： MIA-PaCa-2 cells

原文链接： https://journals.lww.com/anti-cancerdrugs/Fulltext/2020/09000/HOXB5_promotes_proliferation,_migration,_and.8.aspx?context=LatestArticles

PubMed=1764370; DOI=10.1038/bjc.1991.467
Barton C.M., Staddon S.L., Hughes C.M., Hall P.A., O'Sullivan C., Kloppel G., Theis B., Russell R.C.G., Neoptolemos J., Williamson R.C.N., Lane D.P., Lemoine N.R.
Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer.
Br. J. Cancer 64:1076-1082(1991)

PubMed=1630814
Ruggeri B., Zhang S.-Y., Caamano J., DiRado M., Flynn S.D., Klein-Szanto A.J.P.
Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes.
Oncogene 7:1503-1511(1992)

PubMed=7809022; DOI=10.1097/00006676-199409000-00018
Sumi S., Beauchamp R.D., Townsend C.M. Jr., Pour P.M., Ishizuka J., Thompson J.C.
Lovastatin inhibits pancreatic cancer growth regardless of RAS mutation.
Pancreas 9:657-661(1994)

PubMed=7961102; DOI=10.1111/j.1349-7006.1994.tb02898.x
Suwa H., Yoshimura T., Yamaguchi N., Kanehira K., Manabe T., Imamura M., Hiai H., Fukumoto M.
K-ras and p53 alterations in genomic DNA and transcripts of human pancreatic adenocarcinoma cell lines.
Jpn. J. Cancer Res. 85:1005-1014(1994)

PubMed=8026879; DOI=10.1002/ijc.2910580207
Berrozpe G., Schaeffer J., Peinado M.A., Real F.X., Perucho M.
Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer.
Int. J. Cancer 58:185-191(1994)

PubMed=8194712; DOI=10.1016/0016-5085(94)90422-7
Simon B., Weinel R., Hohne M., Watz J., Schmidt J., Kortner G., Arnold R.
Frequent alterations of the tumor suppressor genes p53 and DCC in human pancreatic carcinoma.
Gastroenterology 106:1645-1651(1994)

PubMed=21607521; DOI=10.3892/or.1.6.1223
Iguchi H., Morita R., Yasuda D., Takayanagi R., Ikeda Y., Takada Y., Shimazoe T., Nawata H., Kono A.
Alterations of the p53 tumor-suppressor gene and ki-ras oncogene in human pancreatic cancer-derived cell-lines with different metastatic potential.
Oncol. Rep. 1:1223-1227(1994)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)

PubMed=10027410; DOI=10.1016/S0002-9440(10)65298-4
Ghadimi B.M., Schrock E., Walker R.L., Wangsa D., Jauho A., Meltzer P.S., Ried T.
Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas.
Am. J. Pathol. 154:525-536(1999)

PubMed=11115575; DOI=10.3892/or.8.1.89
Sun C.-L., Yamato T., Furukawa T., Ohnishi Y., Kijima H., Horii A.
Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines.
Oncol. Rep. 8:89-92(2001)

PubMed=11169957; DOI=10.1002/1097-0215(200002)9999:9999<::AID-IJC1014>3.0.CO;2-U
Wallrapp C., Hahnel S., Boeck W., Soder A., Mincheva A., Lichter P., Leder G., Gansauge F., Sorio C., Scarpa A., Gress T.M.
Loss of the Y chromosome is a frequent chromosomal imbalance in pancreatic cancer and allows differentiation to chronic pancreatitis.
Int. J. Cancer 91:340-344(2001)

PubMed=11169959; DOI=10.1002/1097-0215(200002)9999:9999<::AID-IJC1049>3.0.CO;2-C
Sirivatanauksorn V., Sirivatanauksorn Y., Gorman P.A., Davidson J.M., Sheer D., Moore P.S., Scarpa A., Edwards P.A.W., Lemoine N.R.
Non-random chromosomal rearrangements in pancreatic cancer cell lines identified by spectral karyotyping.
Int. J. Cancer 91:350-358(2001)

PubMed=11787853; DOI=10.1007/s004280100474
Moore P.S., Sipos B., Orlandini S., Sorio C., Real F.X., Lemoine N.R., Gress T.M., Bassi C., Kloppel G., Kalthoff H., Ungefroren H., Lohr J.-M., Scarpa A.
Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.
Virchows Arch. 439:798-802(2001)

PubMed=12068308; DOI=10.1038/nature00766
Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Mutations of the BRAF gene in human cancer.
Nature 417:949-954(2002)

PubMed=12692724; DOI=10.1007/s00428-003-0784-4
Sipos B., Moser S., Kalthoff H., Torok V., Lohr J.-M., Kloppel G.
A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform.
Virchows Arch. 442:444-452(2003)

PubMed=14695172
Iacobuzio-Donahue C.A., Ashfaq R., Maitra A., Adsay N.V., Shen-Ong G.L.-C., Berg K., Hollingsworth M.A., Cameron J.L., Yeo C.J., Kern S.E., Goggins M.G., Hruban R.H.
Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies.
Cancer Res. 63:8614-8622(2003)

PubMed=15770730; DOI=10.3748/wjg.v11.i10.1521
Ma J.-H., Patrut E., Schmidt J., Knaebel H.-P., Buchler M.W., Marten A.
Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma.
World J. Gastroenterol. 11:1521-1528(2005)

PubMed=16912165; DOI=10.1158/0008-5472.CAN-06-0721
Calhoun E.S., Hucl T., Gallmeier E., West K.M., Arking D.E., Maitra A., Iacobuzio-Donahue C.A., Chakravarti A., Hruban R.H., Kern S.E.
Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays.
Cancer Res. 66:7920-7928(2006)

PubMed=17254797; DOI=10.1016/j.biologicals.2006.10.001
Azari S., Ahmadi N., Jeddi-Tehrani M., Shokri F.
Profiling and authentication of human cell lines using short tandem repeat (STR) loci: report from the National Cell Bank of Iran.
Biologicals 35:195-202(2007)

PubMed=18298655; DOI=10.1111/j.1582-4934.2008.00289.x
Pilarsky C., Ammerpohl O., Sipos B., Dahl E., Hartmann A., Wellmann A., Braunschweig T., Lohr J.-M., Jesenofsky R., Friess H., Wente M.N., Kristiansen G., Jahnke B., Denz A., Ruckert F., Schackert H.K., Kloppel G., Kalthoff H., Saeger H.-D., Grutzmann R.
Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling.
J. Cell. Mol. Med. 12:2823-2835(2008)

PubMed=18380791; DOI=10.1111/j.1349-7006.2008.00779.x
Suzuki A., Shibata T., Shimada Y., Murakami Y., Horii A., Shiratori K., Hirohashi S., Inazawa J., Imoto I.
Identification of SMURF1 as a possible target for 7q21.3-22.1 amplification detected in a pancreatic cancer cell line by in-house array-based comparative genomic hybridization.
Cancer Sci. 99:986-994(2008)

PubMed=18575732; DOI=10.3892/or.20.1.155
Kawaoka T., Oka M., Takashima M., Ueno T., Yamamoto K., Yahara N., Yoshino S., Hazama S.
Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1.
Oncol. Rep. 20:155-163(2008)

CLPUB00416

Oberlin L.
Treatment of pancreatic carcinoma cell lines in vitro and vivo with a monoclonal antibody against the transferrin receptor.
Thesis VMD (2009), Justus-Liebig-Universitat Giessen, Germany

PubMed=19077451; DOI=10.1159/000178871
Harada T., Chelala C., Crnogorac-Jurcevic T., Lemoine N.R.
Genome-wide analysis of pancreatic cancer using microarray-based techniques.
Pancreatology 9:13-24(2009)

PubMed=19188929; DOI=10.1038/tpj.2008.20
Guo J., Anderson M.G., Tapang P., Palma J.P., Rodriguez L.E., Niquette A.L., Li J.-L., Bouska J.J., Wang G., Semizarov D., Albert D.H., Donawho C.K., Glaser K.B., Shah O.J.
Identification of genes that confer tumor cell resistance to the aurora B kinase inhibitor, AZD1152.
Pharmacogenomics J. 9:90-102(2009)

PubMed=19904223; DOI=10.1097/MPA.0b013e3181bc44dd
Xiao J., Lee W.-N.P., Zhao Y.-C., Cao R., Go V.L.-W., Recker R.R., Wang Q., Xiao G.G.-S.
Profiling pancreatic cancer-secreted proteome using 15N amino acids and serum-free media.
Pancreas 39:E17-E23(2010)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=20418756; DOI=10.1097/MPA.0b013e3181c15963
Deer E.L., Gonzalez-Hernandez J., Coursen J.D., Shea J.E., Ngatia J., Scaife C.L., Firpo M.A., Mulvihill S.J.
Phenotype and genotype of pancreatic cancer cell lines.
Pancreas 39:425-435(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224
Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K., Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.-Y., van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J., Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P., Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L., Rottapel R., Neel B.G., Moffat J.
Essential gene profiles in breast, pancreatic, and ovarian cancer cells.
Cancer Discov. 2:172-189(2012)

DOI=10.4172/2324-9293.1000104
Wagenhauser M.U., Ruckert F., Niedergethmann M., Grutzmann R., Saeger H.-D.
Distribution of characteristic mutations in native ductal adenocarcinoma of the pancreas and pancreatic cancer cell lines.
Cell Biol. Res. Ther. 2:1000104.1-1000104.5(2013)

PubMed=23386380; DOI=10.1002/jcb.24506
Bose B., Shenoy P.S.
Non insulin producing cell line, MIA PaCa-2 is rendered insulin producing in vitro via mesenchymal epithelial transition.
J. Cell. Biochem. 114:1642-1652(2013)